{"id":1047,"date":"2010-09-20T10:59:29","date_gmt":"2010-09-20T14:59:29","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=1047"},"modified":"2010-09-20T10:59:29","modified_gmt":"2010-09-20T14:59:29","slug":"nih-awards-two-small-business-grants-for-skin-disorders","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=1047","title":{"rendered":"NIH Awards Two Small Business Grants for Skin Disorders"},"content":{"rendered":"<p><a href=\"http:\/\/www.signumbiosciences.com\/index.html\">Signum Biosciences Inc.<\/a> in Princeton, New Jersey received two Small Business Innovation Research (SBIR) Phase 1 grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, a division of the NIH, totaling over $684,000 for development of G-protein coupled receptor modulating therapeutics designed to treat common skin disorders. Phase 1 SBIR grants fund proofs-of-concept and test the feasibility of proposed technologies.<\/p>\n<p>With one grant, Signum will develop anti-inflammatory agents to reduce chronic redness (erythema) associated with the relatively common conditions eczema, atopic dermatitis, and rosacea.\u00a0 Signum says <a href=\"http:\/\/www.signumbiosciences.com\/stm_platform.html\">Signal Transduction Modulator<\/a> technology has already demonstrated significant reduction of redness in a double-blinded placebo controlled clinical study.<\/p>\n<p>The second SBIR grant was awarded to fund Signum&#8217;s identification and development of safe and topical anti-acne therapeutics. Acne is a common skin disorder that affects up to 80% of individuals at some point in their lives. Signum&#8217;s STM technology has shown potential to reduce both inflammation and infection associated with acne.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Signum Biosciences Inc. in Princeton, New Jersey received two Small Business Innovation Research (SBIR) Phase 1 grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, a division of the NIH, totaling over $684,000 for development of G-protein coupled receptor modulating therapeutics designed to treat common skin disorders. Phase 1 SBIR grants fund [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[21,38,39,27],"class_list":["post-1047","post","type-post","status-publish","format-standard","hentry","category-finance","tag-biotech","tag-grant","tag-nih","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1047"}],"version-history":[{"count":2,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1047\/revisions"}],"predecessor-version":[{"id":1049,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1047\/revisions\/1049"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}